Three names, all insurance-float compounders, all argued positively. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. Written post with no timestamps — the At link opens the article.
| Ticker | Name | Research | View | What he said | At |
|---|---|---|---|---|---|
| BRK.B | Berkshire Hathaway | QT · SA · STK · FA | Positive | The issue's central recommendation, framed as an index substitute: "today, I think it's a way safer bet to buy Berkshire Hathaway instead of the index." Five reasons listed — better diversified with "no large exposure to AI such as the S&P 500"; a huge cash pile, "one third of the portfolio = cash"; the ability to invest the float; "one of the best capital allocators in the world"; and a valuation "way cheaper than the one of the S&P 500". The mechanism is spelled out: using free float to buy the index would outperform the index "by definition". The timing argument: underperformance of 40% versus the index since Greg Abel's appointment was announced — "This has nothing to do with Greg Abel. It has everything to do with Mr. Market who is a Manic-Depressive. The last time Berkshire underperformed this much? 1999." Long-run record: $10,000 in 1962 → $3.8bn, against $6m for the S&P 500. The concession made: outperformance will be lower than in past decades "due to the law of large numbers". | read ↗ |
| FFH.TO | Fairfax Financial Holdings | QT · SA · STK · FA | Positive | "The Next Berkshire Hathaway" — offered as "another viable alternative for Berkshire Hathaway". "Fairfax is a Canadian insurance and investment company. They collect money from insurance and try to grow it by buying stocks and businesses." Prem Watsa is "called the 'Canadian Warren Buffett'", and the write-up discloses first-hand study: "I just read his excellent book The Fairfax Way and am currently reading his shareholder letters (over 1,000 pages)." Five points: decentralised ownership and accountability (each CEO runs their company independently); long management retention; nimbleness versus large centralised firms; financial flexibility from being able to sell small stakes without losing control; and a track record of "over 19% per year since its IPO in 1985". Upgraded Hold→Buy twelve days earlier; ranked Best Buy #2 on 7 June; bought on 16 August. | read ↗ |
| KNSL | Kinsale Capital Group | QT · SA · STK · FA | Positive | "The Company I pitched in Omaha" — presented from the AGM panel stage. "Kinsale Capital is an established and expanding specialty insurance company focused exclusively on the excess and surplus lines ('E&S') market in the United States… a true compounding machine." Five points: niche market leadership in E&S, where expertise is the advantage; "consistently delivers one of the best combined ratios in the industry"; founder alignment — "Founder and CEO Mike Kehoe still owns 3.9% of the business"; capital-efficient growth reinvesting the insurance float; and a track record of "34.4% annualized return since its IPO in 2016". A standing Very Strong conviction holding across the archive. | read ↗ |
Two observations. (1) All three names are the same trade. Berkshire, Fairfax and Kinsale are each an insurance underwriter that invests its float — so the issue's diversification argument (Berkshire is safer than the index because it avoids AI concentration) sits beside a three-name shortlist concentrated in a single business model and a single risk, underwriting losses. (2) The "underperformed by 40% since Abel" figure is not sourced or dated, and the 1999 analogue is offered without the intervening data — Berkshire's post-1999 outperformance is a fact, but the pattern-match is an argument, not evidence.
A jargon-free summary of the thesis behind each argued name. (Renders on each name's consolidated page.)
The argument here is that Berkshire is a better version of an index fund, and the reason is insurance.
An insurer takes your premium today and pays your claim years later. In between it holds a large pile of your money. That pile is called float. If the insurance business roughly breaks even on its own, the float costs nothing — it is other people's money, invested for free. The worked example given: you pay $1,500 a year for car cover, and the average driver claims $8,000 to $10,000 once every 17 or 18 years. Everything in between gets invested.
From that comes the sharpest claim in the piece: if Berkshire simply bought the S&P 500 with its profits and its float, it would beat the S&P 500 — because it is buying the index with money it did not have to raise.
Four other reasons are given for preferring it to the index right now. It has almost no exposure to the artificial-intelligence companies that dominate the index. A third of the portfolio is cash, ready to spend when prices fall. It is run by exceptional capital allocators. And it is much cheaper than the index.
The timing argument is that the shares have lagged the index by 40% since Greg Abel was named the next chief executive — blamed on sentiment, not on Abel — and that the last comparable lag was 1999, after which Berkshire beat the market for years.
The one caveat given honestly: the company is now so large that future outperformance will be smaller than in the past.
Fairfax runs the same machine as Berkshire, in Canada, and is presented here under the heading "The Next Berkshire Hathaway". It sells insurance, holds the premiums, and invests them in shares and whole businesses. Prem Watsa, who has run it since the beginning, is nicknamed the Canadian Warren Buffett.
What makes it work, according to the write-up, is that it is deliberately decentralised. Each insurance subsidiary has its own chief executive who runs it independently and is judged on its own results; those managers stay for a long time; and because the businesses are legally separate, Fairfax can sell a slice of one to raise money without giving up control of it.
The record is the evidence: shareholders' money has compounded at more than 19% a year since the company listed in 1985 — a forty-year run, long enough that luck is not a plausible explanation.
Worth noting the author is doing the primary work rather than taking the reputation on trust: he has read Watsa's book and is working through more than a thousand pages of shareholder letters.
Kinsale is the company presented from the stage at the Omaha panel. It writes American "excess and surplus lines" insurance — the awkward risks that ordinary insurers turn down. Because these policies fall outside standard rate regulation, the insurer sets its own price, so the whole business is a bet on knowing what a difficult risk is actually worth.
The proof that it does know is the combined ratio, described as one of the best in the industry. That ratio compares claims and expenses to premiums collected; below 100% means the underwriting itself makes money. When it does, the cash held between premium and claim — the float — is genuinely free, and Kinsale reinvests it to fund growth without needing outside capital.
The founder still owns 3.9% of the company, which is the alignment point: Mike Kehoe's own money moves with the shareholders'.
The result so far is a 34.4% annual return since listing in 2016 — the strongest record of the three insurance names discussed in this issue.
Summary derived from the archived Compounding Quality post (text in transcript.txt) for personal study. Not investment advice. © Compounding Quality / Pieter Slegers for source material.